Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Gigavax Aps has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner across 1 distinct art unit. The focus on a single technology area indicates a specialized patent strategy for the company. Practitioners can monitor the specific requirements of this art unit to anticipate potential hurdles. The involvement of 1 distinct examiner means that the prosecution outcome for the current portfolio depends on the evaluation of a single individual. This concentration allows for a highly tailored communication strategy with the patent office.
The busiest examiner identified in the data is OLSON, ALEXANDRA NADINE, who is currently managing 1 pending office action. This single matter accounts for the total pending office actions for the portfolio. Because there is only 1 distinct examiner and 1 distinct art unit, the prosecution environment is highly consolidated. The workload of 1 busiest examiner pending 1 action reflects a lean portfolio at this stage of prosecution. This streamlined structure simplifies the management of deadlines and ensures that all active matters are subject to a consistent examination standard within the assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OLSON, ALEXANDRA NADINE | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18263039 | PMHC MULTIPLEXERS FOR DETECTION OF ANTIGEN-SPECIFIC CELLS | OLSON, ALEXANDRA NADINE | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18263039 | PMHC MULTIPLEXERS FOR DETECTION OF ANTIGEN-SPECIFIC CELLS | OLSON, ALEXANDRA NADINE | 1684 | §102§103§112DP | Non-Final OA | — | Pending | Jul 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGigavax Aps has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexandra Nadine Olson has the most, with 1 of Gigavax Aps's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
